PI3K/Akt/mTOR signaling regulates glutamate transporter 1 in astrocytes

被引:84
|
作者
Wu, Xiaofeng [1 ]
Kihara, Takeshi [1 ]
Akaike, Akinori [2 ]
Niidome, Tetsuhiro [1 ]
Sugimoto, Hachiro [1 ]
机构
[1] Kyoto Univ, Grad Sch Pharmaceut Sci, Dept Neurosci Drug Discovery, Kyoto 6068501, Japan
[2] Kyoto Univ, Grad Sch Pharmaceut Sci, Dept Pharmacol, Kyoto 6068501, Japan
关键词
Astrocyte; Astrocyte-defined medium (ADM); Glutamate uptake; Glutamate transporter 1 (GLT1); Mammalian target of rapamycin (mTOR); Rapamycin; UP-REGULATION; MTOR; MECHANISMS; PATHWAY; GROWTH;
D O I
10.1016/j.bbrc.2010.02.038
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Reduction in or dysfunction of glutamate transporter 1 (GLT1) is linked to several neuronal disorders such as stroke, Alzheimer's disease, and amyotrophic lateral sclerosis. However, the detailed mechanism underlying GLT1 regulation has not been fully elucidated. In the present study, we first demonstrated the effects of mammalian target of rapamycin (mTOR) signaling on GLT1 regulation. We prepared astrocytes cultured in astrocyte-defined medium (ADM), which contains several growth factors including epidermal growth factor (EGF) and insulin. The levels of phosphorylated Akt (Ser473) and mTOR (Ser2448) increased, and GLT1 levels were increased in ADM-cultured astrocytes. Treatment with a phosphatidylinositol 3-kinase (PI3K) inhibitor or an Akt inhibitor suppressed the phosphorylation of Akt (Ser473) and mTOR (Ser2448) as well as decreased ADM-induced GLT1 upregulation. Treatment with the mTOR inhibitor rapamycin decreased GLT1 protein and mRNA levels. In contrast, rapamycin did not affect Akt (Ser473) phosphorylation. Our results suggest that mTOR is a downstream target of the PI3K/Akt pathway regulating GLT1 expression. (C) 2010 Elsevier Inc. All rights reserved.
引用
收藏
页码:514 / 518
页数:5
相关论文
共 50 条
  • [1] The PI3K/Akt/mTOR signaling pathway
    Dennis, P. A.
    ANNALS OF ONCOLOGY, 2011, 22 : 19 - 19
  • [2] PI3K/AKT/mTOR Signaling Pathway Is Required for JCPyV Infection in Primary Astrocytes
    Wilczek, Michael P.
    Armstrong, Francesca J.
    Mayberry, Colleen L.
    King, Benjamin L.
    Maginnis, Melissa S.
    CELLS, 2021, 10 (11)
  • [3] Targeting PI3K/Akt/mTOR signaling in cancer
    Porta, Camillo
    Paglino, Chiara
    Mosca, Alessandra
    FRONTIERS IN ONCOLOGY, 2014, 4
  • [4] RAS Signaling in the PI3K/AKT/MTOR Pathway
    Nussinov, Ruth
    Zhang, Mingzhen
    Jang, Hyunbum
    BIOPHYSICAL JOURNAL, 2020, 118 (03) : 51A - 51A
  • [5] PI3K/AKT/MTOR SIGNALING IN OLIGODENDROCYTE DIFFERENTIATION
    Wood, T. L.
    Tyler, W. A.
    Gangoli, N.
    Gokina, P.
    Kim, H. A.
    Covey, M.
    Levison, S. W.
    JOURNAL OF NEUROCHEMISTRY, 2009, 110 : 141 - 141
  • [6] The PI3K/AKT/MTOR signaling pathway: The role of PI3K and AKT inhibitors in breast cancer
    Huemer F.
    Bartsch R.
    Gnant M.
    Current Breast Cancer Reports, 2014, 6 (2) : 59 - 70
  • [7] PI3K/AKT/mTOR
    Umemura, Shigeki
    Goto, Koichi
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S116 - S117
  • [8] PI3K/AKT/mTOR signaling regulates BCP ceramic-induced osteogenesis
    Tan, Peijie
    Hua, Yuchen
    Yuan, Bo
    Liu, Xiaoyang
    Chen, Xuening
    Zeng, Wei-Nan
    Zeng, Qin
    Zhu, Xiangdong
    Zhang, Xingdong
    JOURNAL OF MATERIALS CHEMISTRY B, 2024, 12 (31) : 7591 - 7603
  • [9] Scutellarin regulates osteoarthritis in vitro by inhibiting the PI3K/AKT/mTOR signaling pathway
    Ju, Shao-Hua
    Tan, Li-Rong
    Liu, Pan-Wang
    Tan, You-Li
    Zhang, Yuan-Ting
    Li, Xiao-Hong
    Wang, Ming-Jian
    He, Ben-Xiang
    MOLECULAR MEDICINE REPORTS, 2021, 23 (01)
  • [10] PI3K/mTOR Signaling Regulates Prostatic Tubulogenesis
    Ghosh, S.
    Lau, H.
    Simons, B.
    Berman, D.
    Lotan, T. L.
    MODERN PATHOLOGY, 2011, 24 : 391A - 391A